Acoramidis Data to Be Shown at Heart Meeting
Adults with ATTR-CM and their cardiologists can review updated acoramidis evidence at the AHA Scientific Sessions in Chicago this November.
Updated on Nov. 3, 2026 in Heart Disease
BridgeBio Pharma will present acoramidis data at the American Heart Association Scientific Sessions 2026 in Chicago, November 6-9, 2026. Readers with transthyretin amyloid cardiomyopathy (ATTR-CM), a heart condition caused by misfolded transthyretin protein, can follow the presentations as updated evidence on the drug, which is approved in the United States as Attruby.
Why it matters
The presentations bring together acoramidis data, including poster sessions on ATTR-CM, at a major cardiology meeting, giving clinicians and patients a current look at how the therapy is being studied and used. Acoramidis is already approved in several countries, so these sessions focus on updated evidence rather than a new launch.
The posters draw on the ATTRibute-CM trial, which compared Attruby with placebo in patients with ATTR-CM. Among the reported side effects, diarrhea rose to 11.6% with Attruby compared with 7.6% on placebo, and upper abdominal pain to 5.5% versus 1.4%.
The players
BridgeBio Pharma
A commercial-stage biopharmaceutical company focused on genetic conditions, headquartered in Palo Alto, California, and developer of acoramidis for ATTR-CM.
Abbott Laboratories
A global healthcare company whose diagnostics work includes transthyretin detection assays, with one poster presentation at the AHA Scientific Sessions 2026.
American Heart Association
A leading U.S. nonprofit focused on cardiovascular health, which hosts the Scientific Sessions where the posters will be presented.
U.S. Food and Drug Administration
The U.S. federal agency responsible for approving drugs, which approved acoramidis as Attruby for ATTR-CM in adults.
The details
Acoramidis is an orally administered, selective small molecule that stabilizes transthyretin, a protein made in the liver that can misfold and build up in the heart muscle in ATTR-CM. The sessions will include two moderated posters and three standard posters on acoramidis and ATTR-CM, along with a BridgeBio-supported poster led by Abbott Laboratories on transthyretin detection assays.
Timeline
November 6-9, 2026: American Heart Association Scientific Sessions in Chicago, Illinois.
November 8, 2026: Acoramidis ATTRibute-CM poster presentations at 3:15 pm CT.
November 9, 2026: Moderated poster presentations and the Abbott-led poster session.
Health Landscape
Acoramidis is approved as Attruby by the U.S. FDA and as BEYONTTRA by the European Medicines Agency, and is also approved in Japan, Switzerland, the United Kingdom, Brazil, and Australia. The Chicago sessions add to a growing body of post-approval research on how transthyretin stabilizers are used in ATTR-CM.
If you or a family member has been diagnosed with ATTR-CM, the new data may be worth raising with your cardiologist, especially the side-effect rates in the trial, such as diarrhea and upper abdominal pain. Because these are population-level findings from a trial, any decision about treatment should be discussed with your physician.
The takeaway
The sessions offer an updated look at acoramidis evidence for ATTR-CM, including side-effect data from the ATTRibute-CM trial. Readers with questions about whether this therapy fits their situation should bring them to their cardiologist.
What happens next
The AHA Scientific Sessions run November 6-9, 2026 in Chicago, with acoramidis poster presentations on November 8 at 3:15 pm CT and additional moderated and Abbott-led poster sessions on November 9.
Further reading
For more on the condition at the center of these posters, see our Heart Disease coverage.
